Clinical Trial: Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07106892) titled 'Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer' on July 30.

Brief Summary: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Colorectal Cancer (CRC)

Study Start Date: Aug. 15

Study Type: INTERVENTIONAL

Condition: Colorectal Cancer (CRC)

Intervention: DRUG: HLX43 Dose 1;

HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ra...